Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis
Meta-analysis supports infliximab use in pulmonary sarcoidosis, although improvements in lung function are modest. There is limited but promising evidence for the use of adalimumab and tofacitinib in cutaneous disease and efzofitimob in pulmonary disease. Study interpretation is limited by small sample sizes and heterogeneity in study design and population.PROSPERO registration numberCRD42024599560.
Authors
- James Benjamin Galloway (ORCID: https://orcid.org/0000-0002-1230-2781)
- Mark Russell (ORCID: https://orcid.org/0000-0001-8171-7772)
- Sarah Walsh (ORCID: https://orcid.org/0000-0002-8279-0506)
- Surinder Singh Birring (ORCID: https://orcid.org/0000-0003-2525-6291)
- Katherine Myall (ORCID: https://orcid.org/0000-0002-9094-4077)
- Sam Norton (ORCID: https://orcid.org/0000-0003-1714-9963)
- Katie Bechman (ORCID: https://orcid.org/0000-0001-7552-0463)
- Kai He (ORCID: https://orcid.org/0000-0003-0508-8411)
- Kathryn Biddle (ORCID: https://orcid.org/0000-0001-5267-200X)
- Aitana Miracle
- Amit Patel
- Mark Gibson
- Peter Brex
Institutions
- King's College London (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Asthma UK (GB)
Publication Details
- Journal
- Thorax
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1136/thorax-2025-223014
- Citations
- 6
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 6.99
Funders
- National Institute for Health and Care Research
- Innovate UK